Derek M Meisner, serving as Chief Legal Officer and Corporate Secretary of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), completed the sale of 8,934 shares of the company’s common stock through a series of transactions reported in a Securities and Exchange Commission Form 4 filing. These stock dispositions occurred between January 21 and January 23, 2026, with sale prices averaging between $1.8083 and $1.9027 per share, cumulatively garnering approximately $16,720.
On January 21, Meisner sold 2,247 shares via multiple trades, where per-share prices ranged from $1.7600 to $1.8700. Subsequently, on January 22, he sold 1,054 shares at a consistent price of $1.84 each. The largest portion of the sales took place on January 23, when Meisner executed the disposition of 5,633 shares at prices spanning from $1.8800 to $1.9400 in several transactions. These sales were conducted under a pre-established Rule 10b5-1 trading plan, a mechanism permitting scheduled security transactions by insiders.
Following these executions, Meisner retains a direct ownership stake of 173,999 shares in Acumen Pharmaceuticals.
In related developments, Acumen Pharmaceuticals recently announced a net loss of $26.5 million for the third quarter of 2025. Despite the financial setback, the company maintains a strategic emphasis on advancing its Alzheimer’s disease therapies, particularly its lead candidate, Sabirnetug. The organization has commenced an open-label extension phase of its Phase 2 ALTITUDE-AD clinical trial, providing Sabirnetug treatment to participants for an additional 52 weeks.
Moreover, Acumen highlighted its ongoing research related to improved delivery techniques for Alzheimer’s therapeutics at the 18th Annual Clinical Trials on Alzheimer’s Disease conference. The firm’s collaboration with JCR Pharmaceuticals focuses on enhancing antibody delivery to the central nervous system, a crucial innovation in therapeutic efficacy for neurological conditions. The continued advancement of the company’s development pipeline has garnered positive market consideration, as evidenced by Stifel’s reaffirmed Buy rating and $10.00 price target on Acumen Pharmaceuticals.
These moves mark sustained commitment from Acumen Pharmaceuticals to cultivate viable treatment strategies in the challenging neurodegenerative disease sector, notwithstanding recent financial losses.